Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.
2.

Age and adjuvant chemotherapy use after surgery for stage III colon cancer.

Schrag D, Cramer LD, Bach PB, Begg CB.

J Natl Cancer Inst. 2001 Jun 6;93(11):850-7.

PMID:
11390534
3.

Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.

Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL.

J Clin Oncol. 2006 May 20;24(15):2368-75.

PMID:
16618946
4.

Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.

Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD.

J Am Geriatr Soc. 2009 Aug;57(8):1403-10. doi: 10.1111/j.1532-5415.2009.02355.x.

PMID:
19563521
5.

Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer.

Hu CY, Chan W, Delclos GP, Du XL.

Am J Clin Oncol. 2012 Jun;35(3):228-36. doi: 10.1097/COC.0b013e318210f812.

PMID:
21383605
6.

Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer.

Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, Neugut AI.

Cancer. 2006 Dec 1;107(11):2581-8.

7.

Completion of therapy by Medicare patients with stage III colon cancer.

Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W.

J Natl Cancer Inst. 2006 May 3;98(9):610-9.

8.

The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer.

Gross CP, McAvay GJ, Guo Z, Tinetti ME.

Cancer. 2007 Jun 15;109(12):2410-9.

9.

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.

Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI.

Ann Intern Med. 2002 Mar 5;136(5):349-57.

PMID:
11874307
10.

Referral patterns and adjuvant chemotherapy use in patients with stage II colon cancer.

Kirkpatrick HM, Aitelli CL, Qin H, Becerra C, Lichliter WE, McCollum AD.

Clin Colorectal Cancer. 2010 Jul;9(3):150-6. doi: 10.3816/CCC.2010.n.020.

PMID:
20643619
11.

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524.

12.

Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data.

Hanna NN, Onukwugha E, Choti MA, Davidoff AJ, Zuckerman IH, Hsu VD, Mullins CD.

Colorectal Dis. 2012 Jan;14(1):48-55. doi: 10.1111/j.1463-1318.2011.02545.x.

PMID:
21689262
13.

Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Clin Colorectal Cancer. 2013 Jun;12(2):113-21. doi: 10.1016/j.clcc.2012.09.007.

PMID:
23137529
14.

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.

Cancer. 2012 Sep 1;118(17):4309-20. doi: 10.1002/cncr.27422.

15.

Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer.

Hsieh MC, Chiu YW, Velasco C, Wu XC, O'Flarity MB, Chen VW.

J Registry Manag. 2013 Winter;40(4):180-7.

PMID:
24625772
16.

Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients.

Mahoney T, Kuo YH, Topilow A, Davis JM.

Arch Surg. 2000 Feb;135(2):182-5.

PMID:
10668878
17.

Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.

Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, Fuchs CS.

J Clin Oncol. 2011 Aug 20;29(24):3255-62. doi: 10.1200/JCO.2011.35.0058. Erratum in: J Clin Oncol. 2012 Jan 20;30(3):343.

PMID:
21768462
18.

Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer.

Gibbs P, Handolias D, McLaughlin S, Chapman M, Johns J, Faragher I.

Intern Med J. 2008 Apr;38(4):265-9. doi: 10.1111/j.1445-5994.2007.01520.x.

PMID:
18298558
19.

Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.

Fata F, Mirza A, Craig G, Nair S, Law A, Gallagher J, Ellison N, Bernath A.

Cancer. 2002 Apr 1;94(7):1931-8. Review.

20.

Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline.

Jonker DJ, Spithoff K, Maroun J; Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care..

Clin Oncol (R Coll Radiol). 2011 Jun;23(5):314-22. doi: 10.1016/j.clon.2011.02.010.

PMID:
21397476
Items per page

Supplemental Content

Support Center